Literature DB >> 23051143

Invasive pulmonary aspergillosis in non-neutropenic patients with and without underlying disease: a single-centre retrospective analysis of 52 subjects.

Zhichu Dai1, Haijin Zhao, Shaoxi Cai, Yanhua Lv, Wancheng Tong.   

Abstract

BACKGROUND AND
OBJECTIVE: Invasive pulmonary aspergillosis (IPA) remains a life-threatening infection in patients with prolonged neutropenia. Few data are available on IPA in non-neutropenic patients without underlying immunocompromising conditions.
METHODS: All non-neutropenic patients managed at the institution for a proven and probable IPA over the last 10 years were reviewed retrospectively, and the difference between non-neutropenic patients with and without underlying disease was investigated.
RESULTS: Among 52 cases of IPA analysed here, 33 were histologically proven; 19 were probable. Forty-two (80.8%) patients had underlying diseases; 10 (19.2%) patients had no any underlying diseases. There is a significant difference in seasonal distribution among patients with underlying conditions (P = 0.026), but no seasonal difference was found in the other group (P = 0.622). The only significant difference in symptoms between the two groups was fever (P = 0.015). Radiological findings were non-specific in the two groups. Despite treatment, the overall crude mortality rate among 52 patients was 39%. The overall mortality rate in patients with underlying disease was 45%, while that in patients without underlying conditions was 11%. A Cox multivariate analysis showed that organ failure (hazard ratios: 8.739, 95% CI: 3.770-20.255; P = 0.000) was independently associated with overall mortality.
CONCLUSIONS: Clinical features of IPA are not well known in non-neutropenic patients, especially in those without underlying conditions. In this study, organ failure was associated with a lower rate of survival of non-neutropenic patients with IPA.
© 2012 The Authors. Respirology © 2012 Asian Pacific Society of Respirology.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23051143     DOI: 10.1111/j.1440-1843.2012.02283.x

Source DB:  PubMed          Journal:  Respirology        ISSN: 1323-7799            Impact factor:   6.424


  11 in total

1.  Quantitative Real-Time PCR and Platelia Galactomannan Assay for the Diagnosis of Invasive Pulmonary Aspergillosis: Bronchoalveolar Lavage Fluid Performs Better Than Serum in Non-neutropaenic Patients.

Authors:  Shuzhen Zhang; Sibu Wang; Zhe Wan; Chengli Que; Ruoyu Li; Jin Yu
Journal:  Mycopathologia       Date:  2016-06-07       Impact factor: 2.574

2.  Pulmonary Fungal Diseases in Immunocompetent Hosts: A Single-Center Retrospective Analysis of 35 Subjects.

Authors:  XiaoPei Yan; Feng Zong; Hui Kong; YanLi Wang; XinYun Zhao; WenRui Liu; ZaiLiang Wang; WeiPing Xie
Journal:  Mycopathologia       Date:  2016-05-13       Impact factor: 2.574

3.  Prognosis of Invasive Aspergillosis in Kidney Transplant Recipients: A Case-Control Study.

Authors:  Anne-Claire Desbois; Sylvain Poiree; Renaud Snanoudj; Marie-Elisabeth Bougnoux; Rebecca Sberro-Soussan; Fanny Lanternier; Christophe Legendre; Olivier Lortholary; Anne Scemla
Journal:  Transplant Direct       Date:  2016-07-01

4.  Galactomannan in Bronchoalveolar Lavage Fluid for Diagnosis of Invasive Pulmonary Aspergillosis with Nonneutropenic Patients.

Authors:  Qidong Zhuang; Hongying Ma; Yun Zhang; Lei Chen; Li Wang; Lin Zheng; Zaichun Deng; Zhongbo Chen
Journal:  Can Respir J       Date:  2017-11-13       Impact factor: 2.409

Review 5.  Challenges and Solution of Invasive Aspergillosis in Non-neutropenic Patients: A Review.

Authors:  Matteo Bassetti; Maddalena Peghin; Antonio Vena
Journal:  Infect Dis Ther       Date:  2017-12-22

6.  The changes of expressive levels of IL-17A, STAT3, and RORγt in different invasive pulmonary aspergillosis mice.

Authors:  Lingna N Xu; Ren-Ai Xu; Dan Zhang; Shanshan S Su; Hanyan Y Xu; Qing Wu; Yuping P Li
Journal:  Infect Drug Resist       Date:  2018-08-27       Impact factor: 4.003

7.  Comparison of Clinical Manifestation, Diagnosis, and Outcomes of Invasive Pulmonary Aspergillosis and Pulmonary Mucormycosis.

Authors:  Chun-Yu Lin; I-Ting Wang; Che-Chia Chang; Wei-Chun Lee; Wei-Lun Liu; Yu-Chen Huang; Ko-Wei Chang; Hung-Yu Huang; Hsuan-Ling Hsiao; Kuo-Chin Kao; Chung-Chi Huang; George Dimopoulos
Journal:  Microorganisms       Date:  2019-11-05

Review 8.  How to manage aspergillosis in non-neutropenic intensive care unit patients.

Authors:  Matteo Bassetti; Elda Righi; Gennaro De Pascale; Raffaele De Gaudio; Antonino Giarratano; Tereesita Mazzei; Giulia Morace; Nicola Petrosillo; Stefania Stefani; Massimo Antonelli
Journal:  Crit Care       Date:  2014-07-25       Impact factor: 9.097

9.  Invasive Pulmonary Aspergillosis with Disseminated Infection in Immunocompetent Patient.

Authors:  Gabriel Moreno-González; Antoni Ricart de Mesones; Rachid Tazi-Mezalek; Maria Teresa Marron-Moya; Antoni Rosell; Rafael Mañez
Journal:  Can Respir J       Date:  2016-05-05       Impact factor: 2.409

10.  Potential value of serum Aspergillus IgG antibody detection in the diagnosis of invasive and chronic pulmonary aspergillosis in non-agranulocytic patients.

Authors:  Qihong Yu; Jingdong He; Bin Xing; Xin Li; Hongyu Qian; Hong Zhang; Meilin Xu; Haiying Peng
Journal:  BMC Pulm Med       Date:  2020-04-15       Impact factor: 3.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.